These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 9815799)

  • 1. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients.
    Murakami I; Hiyama K; Ishioka S; Yamakido M; Kasagi F; Yokosaki Y
    Clin Cancer Res; 2000 Feb; 6(2):526-30. PubMed ID: 10690534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
    Miyatake K; Gemba K; Ueoka H; Nishii K; Kiura K; Tabata M; Shibayama T; Takigawa N; Kawaraya M; Tanimoto M
    Anticancer Res; 2003; 23(3C):2829-36. PubMed ID: 12926120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer.
    Oshita F; Ikehara M; Sekiyama A; Hamanaka N; Saito H; Yamada K; Noda K; Kameda Y; Miyagi Y
    J Exp Ther Oncol; 2004 Jul; 4(2):155-60. PubMed ID: 15500010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.
    Ebina M; Steinberg SM; Mulshine JL; Linnoila RI
    Cancer Res; 1994 May; 54(9):2496-503. PubMed ID: 7909277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of deltaNp73 predicts poor prognosis in lung cancer.
    Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Morita M; Funa K; Yasumoto K
    Clin Cancer Res; 2004 Oct; 10(20):6905-11. PubMed ID: 15501968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
    Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
    Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment.
    Hiraki A; Ueoka H; Yoshino T; Chikamori K; Onishi K; Kiura K; Bessho A; Mimoto J; Date H; Ando A; Shimizu N; Harada M
    Oncol Rep; 1999; 6(1):75-80. PubMed ID: 9864405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lung cancer in women: clinical features and factors related to survival].
    Sen E; Kaya A; Erol S; Savas I; Gonullu U
    Tuberk Toraks; 2008; 56(3):266-74. PubMed ID: 18932027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time.
    Ohsaki Y; Toyoshima E; Fujiuchi S; Matsui H; Hirata S; Miyokawa N; Kubo Y; Kikuchi K
    Clin Cancer Res; 1996 May; 2(5):915-20. PubMed ID: 9816250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas.
    Mørkve O; Halvorsen OJ; Skjaerven R; Stangeland L; Gulsvik A; Laerum OD
    Anticancer Res; 1993; 13(3):571-8. PubMed ID: 8391242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
    Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
    BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma.
    Dalquen P; Sauter G; Torhorst J; Schultheiss E; Jordan P; Lehmann S; Solèr M; Stulz P; Mihatsch MJ; Gudat F
    J Pathol; 1996 Jan; 178(1):53-8. PubMed ID: 8778317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.